Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications

References

• Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation106, 3143–3421 (2002).
   Google Scholar
• Meigs JB, D’Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes46, 1594–1600 (1997).
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA287, 356–359 (2002).
   PubMed Web of Science ®Google Scholar
• Chan DC, Barrett HP, Watts GF. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am. J. Cardiovasc. Drugs4, 227–246 (2004).
   PubMedGoogle Scholar
• Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int. J. Clin. Pract.61, 737–747 (2007).
   PubMed Web of Science ®Google Scholar
• Bays H, Blonde L, Rosenson R. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Exp. Rev. Cardiovasc. Ther.4, 871–895 (2006).
   PubMedGoogle Scholar
• Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol.1, 389–420 (2006).
   Web of Science ®Google Scholar
• Athyros VG, Giouleme OI, Nikolaidis NL et al. Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J. Clin. Gastroenterol.34, 472–475 (2002).
   PubMed Web of Science ®Google Scholar
• Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J. Clin. Gastroenterol.36, 54–62 (2003).
   PubMed Web of Science ®Google Scholar
• Kyriakidis AV, Raitsiou B, Sakagianni A et al. Management of acute severe hyperlipidemic pancreatitis. Digestion73, 259–264 (2006).
   PubMed Web of Science ®Google Scholar
• Fortson MR, Freedman SN, Webster PD III. Clinical assessment of hyperlipidemic pancreatitis. Am. J. Gastroenterol.90, 2134–2139 (1995).
   PubMed Web of Science ®Google Scholar
• Hopkins PN, Heiss G, Ellison RC et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case–control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation108, 519–523 (2003).
   PubMed Web of Science ®Google Scholar
• Veerkamp MJ, de Graaf J, Bredie SJH, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler. Thromb. Vasc. Biol.22, 274–282 (2002).
   PubMed Web of Science ®Google Scholar
• Suviolahti E, Lilja HE, Pajukanta P. Unraveling the complex genetics of familial combined hyperlipidemia. Ann. Med.38, 337–351 (2006).
   PubMed Web of Science ®Google Scholar
• Garcia-Otin AL, Civeira F, Peinado-Onsurbe J, Gonzalvo C, Llobera M, Pocovi M. Acquired lipoprotein lipase deficiency associated with chronic urticaria. A new etiology for type I hyperlipoproteinemia. Eur. J. Endocrinol.141, 502–505 (1999).
   PubMed Web of Science ®Google Scholar
• Nauck MS, Nissen H, Hoffmann MM et al. Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia. Clin. Chem.44, 1388–1396 (1998).
   PubMed Web of Science ®Google Scholar
• Heath RB, Karpe F, Milne RW, Burdge GC, Wootton SA, Frayn KN. Selective partitioning of dietary fatty acids into the VLDL TG pool in the early postprandial period. J. Lipid Res.44, 2065–2072 (2003).
   PubMed Web of Science ®Google Scholar
• Schneeman BO, Kotite L, Todd KM, Havel RJ. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc. Natl Acad. Sci. USA90, 2069–2073 (1993).
   PubMed Web of Science ®Google Scholar
• Gan SI, Edwards AL, Symonds CJ, Beck PL. Hypertriglyceridemia-induced pancreatitis: A case-based review. World J. Gastroenterol.12, 7197–7202 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang JQ, Ji LL, Fogt DL, Fretwell VS. Effect of exercise duration on postprandial hypertriglyceridemia in men with metabolic syndrome. J. Appl. Physiol.103, 1339–1345 (2007).
   PubMed Web of Science ®Google Scholar
• Nishijima H, Satake K, Igarashi K, Morita N, Kanazawa N, Okita K. Effects of exercise in overweight Japanese with multiple cardiovascular risk factors. Med. Sci. Sports Exerc.39, 926–933 (2007).
   PubMed Web of Science ®Google Scholar
• Gardner CD, Kiazand A, Alhassan S et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA297, 969–977 (2007).
   PubMed Web of Science ®Google Scholar
• Monga A, Arora A, Makkar RP, Gupta AK. Hypertriglyceridemia-induced acute pancreatitis – treatment with heparin and insulin. Indian J. Gastroenterol.22, 102–103 (2003).
   PubMedGoogle Scholar
• Loo Chee-Chuen , Tan JYL. Decreasing the plasma triglyceride level in hypertriglycerideia-induced pancreatitis in pregnancy: a case report. Am. J. Obstet. Gynecol.187, 241–242 (2002).
   PubMed Web of Science ®Google Scholar
• Gursoy A, Kulaksizoglu M, Sahin M et al. Severe hypertriglyceridemia-induced pancreatitis during pregnancy. J. Natl Med. Assoc.98, 655–657 (2006).
   PubMed Web of Science ®Google Scholar
• Oh RC, Lanier JB. Management of hypertriglyceridemia. Am. Fam. Physician75, 1365–1371 (2007).
   PubMed Web of Science ®Google Scholar
• Bays H, Stein EA. Pharmacotherapy for dyslipidaemia – current therapies and future agents. Expert Opin. Pharmacother.4, 1901–1938 (2003).
   PubMed Web of Science ®Google Scholar
• Harper CR, Jacobson TA. An evidence-based approach to the use of combination drug therapy for mixed dyslipidemia. JCOM13, 57 (2006).
   Google Scholar
• Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ. Lipids, sterols, and their metabolites. In: Modern Nutrition in Health and Disease (10th Edition). Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ (Eds). Lippincott Williams & Wilkins (2007).
   Google Scholar
• Berg JM, Tymoczko JL, Stryer L. Biochemistry (6th Edition). WH Freeman and Company, NY, USA (2007).
   Google Scholar
• Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res.36, 232–240 (2005).
   PubMed Web of Science ®Google Scholar
• Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler. Thromb. Vasc. Biol.19, 2474–2486 (1999).
   PubMed Web of Science ®Google Scholar
• Marcoux C, Hopkins PN, Wang T et al. Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state. J. Lipid Res.41, 1428–1436 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson DE, Hata A, Kwong LK et al. Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyceridemia, pancreatitis, and non-insulin-dependent diabetes. J. Clin. Invest.92, 203–211 (1993).
   PubMed Web of Science ®Google Scholar
• Jap TS, Jenq SF, Wu YC, Chiu CY, Cheng HM. Mutations in the lipoprotein lipase gene as a cause of hypertriglyceridemia and pancreatitis in Taiwan. Pancreas27, 122–126 (2003).
   PubMed Web of Science ®Google Scholar
• Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipedmia. Future Cardiol.39–59 (2005).
   PubMedGoogle Scholar
• Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of Type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab.89, 463–478 (2004).
   PubMed Web of Science ®Google Scholar
• Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Sem. Liver Dis.21, 27–41 (2001).
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni G, Candelaresi C, Saccomanno S et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am. J. Pathol.169, 846–860 (2006).
   PubMed Web of Science ®Google Scholar
• Julius U. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp. Clin. Endocrinol. Diabetes111, 246–250 (2003).
   PubMed Web of Science ®Google Scholar
• Millar JS, Stone SJ, Tietge UJ et al. Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production. J. Lipid Res.47, 2297–2305 (2006).
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation106, 2137–2142 (2002).
   PubMed Web of Science ®Google Scholar
• McKenney J. Dyslipidemias, atherosclerosis, and coronary heart disease. In: Applied Therapeutics: The Clinical Use of Drugs (8th Edition). Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, Alldredge BK (Eds). Lipincott, Williams and Wilkins (2005).
   Google Scholar
• Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ176, 1113–1120 (2007).
   PubMed Web of Science ®Google Scholar
• Fung MA, Frohlich JJ. Common problems in the management of hypertriglyceridemia. CMAJ167, 1261–1266 (2002).
   PubMed Web of Science ®Google Scholar
• Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, Type 2 diabetes mellitus, and familial combined hyperlipidemia. Am. J. Cardiol.92, 27J–33J (2003).
   PubMed Web of Science ®Google Scholar
• Dunbar RL, Rader DJ. Demystifying triglycerides: a practical approach for the clinician. Cleve. Clin. J. Med.72, 661–680 (2005).
   PubMed Web of Science ®Google Scholar
• Vakkilainen J, Jauhiainen M, Ylitalo K et al. LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J. Lipid Res.43, 598–603 (2002).
   PubMed Web of Science ®Google Scholar
• Davignon J, Genest J Jr. Genetics of lipoprotein disorders. Endocrinol. Metab. Clin. North Am.27, 521–550 (1998).
   PubMed Web of Science ®Google Scholar
• Nagasaka H, Kikuta H, Chiba H et al. Two cases with transient lipoprotein lipase (LPL) activity impairment: evidence for the possible involvement of an LPL inhibitor. Eur. J. Pediatr.162, 132–138 (2003).
   PubMed Web of Science ®Google Scholar
• Smelt AH, de BF. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. Sem. Vasc. Med.4, 249–257 (2004).
   PubMedGoogle Scholar
• Siri PW, Krauss RM. Influence of dietary carbohydrate and fat on LDL and HDL particle distributions. Curr. Atheroscler. Rep.7, 455–459 (2005).
   PubMedGoogle Scholar
• Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol.81, 7B–12B (1998).
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation115, 450–458 (2007).
   PubMed Web of Science ®Google Scholar
• Jones JD. Hypertriglyceridemia and coronary heart disease. Arch. Fam. Med.9, 189–190 (2000).
   PubMedGoogle Scholar
• Assmann G, Schulte H, Cullen P. New and classical risk factors the Munster heart study (PROCAM). Eur. J. Med. Res.2, 237–242 (1997).
   PubMedGoogle Scholar
• Stampfer MJ, Krauss RM, Ma J et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA276, 882–888 (1996).
   PubMed Web of Science ®Google Scholar
• Sniderman AD. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is.. Circulation112, 3366–3367 (2005).
   PubMed Web of Science ®Google Scholar
• Ingelsson E, Sullivan LM, Murabito JM et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes56, 1718–1726 (2007).
   PubMed Web of Science ®Google Scholar
• Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am. J. Cardiol. (2008) (In Press).
   Google Scholar
• Durrington PN. Can measurement of apolipoprotein B replace the lipid profile in the follow-up of patients with lipoprotein disorders? Clin. Chem.48, 401–402 (2002).
   PubMed Web of Science ®Google Scholar
• Bays H, McKenney J, Davidson M. Torcetrapib/atorvastatin combination therapy. Exp. Rev. Cardiovasc. Ther.3, 789–820 (2005).
   PubMedGoogle Scholar
• Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA286, 1468–1474 (2001).
   PubMed Web of Science ®Google Scholar
• Pastromas S, Terzi AB, Tousoulis D, Koulouris S. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus. Int. J. Cardiol. (2007).
   PubMedGoogle Scholar
• Marschang P, Gotsch C, Kirchmair R, Kaser S, Kahler CM, Patsch JR. Postprandial, but not postabsorptive low-density lipoproteins increase the expression of intercellular adhesion molecule-1 in human aortic endothelial cells. Atherosclerosis186, 101–106 (2006).
   PubMed Web of Science ®Google Scholar
• Vine DF, Takechi R, Russell JC, Proctor SD. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis190, 282–290 (2007).
   PubMed Web of Science ®Google Scholar
• Lopez-Miranda J, Perez-Martinez P, Marin C, Moreno JA, Gomez P, Perez-Jimenez F. Postprandial lipoprotein metabolism, genes and risk of cardiovascular disease. Curr. Opin. Lipidol.17, 132–138 (2006).
   PubMed Web of Science ®Google Scholar
• Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation60, 473–485 (1979).
   PubMed Web of Science ®Google Scholar
• Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler. Thromb. Vasc. Biol.16, 697–704 (1996).
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Stender S, Kjeldsen K. Severe hypertriglyceridemia, large lipoproteins and protection against atherosclerosis. Scand. J. Clin. Lab. Invest. Suppl.186, 7–12 (1987).
   PubMedGoogle Scholar
• Silveira A. Postprandial triglycerides and blood coagulation. Exp. Clin. Endocrinol. Diabetes109, S527–S532 (2001).
   Google Scholar
• Sacks FM, Alaupovic P, Moye LA et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation102, 1886–1892 (2000).
   PubMed Web of Science ®Google Scholar
• Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation114, 681–687 (2006).
   PubMed Web of Science ®Google Scholar
• Rahm JJ, Holman RT. The relationship of single dietary polyunsaturated fatty acids to fatty acid composition of lipids from subcellular particles of liver. J. Lipid Res.169–176 (2007).
   PubMed Web of Science ®Google Scholar
• Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J. Biol. Chem.277, 8755–8758 (2002).
   PubMed Web of Science ®Google Scholar
• Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr.83, 1467S–1476S (2006).
   PubMed Web of Science ®Google Scholar
• Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation106, 2747–2757 (2002).
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA296, 1885–1899 (2006).
   PubMed Web of Science ®Google Scholar
• Harris WS, Ginsberg HN, Arunakul N et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J. Cardiovasc. Risk4, 385–391 (1997).
   PubMedGoogle Scholar
• Harris WS. n-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids31, 243–252 (1996).
   PubMed Web of Science ®Google Scholar
• Lewis A, Lookinland S, Beckstrand RL, Tiedeman ME. Treatment of hypertriglyceridemia with omega-3 fatty acids: a systematic review. J. Am. Acad. Nurse Pract.16, 384–395 (2004).
   PubMedGoogle Scholar
• Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J. Lipid Res.44, 455–463 (2003).
   PubMed Web of Science ®Google Scholar
• Williams CM, Moore F, Morgan L, Wright J. Effects of n-3 fatty acids on postprandial triacylglycerol and hormone concentrations in normal subjects. Br. J. Nutr.68, 655–666 (1992).
   PubMed Web of Science ®Google Scholar
• Weintraub MS, Zechner R, Brown A, Eisenberg S, Breslow JL. Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J. Clin. Invest.82, 1884–1893 (1988).
   PubMed Web of Science ®Google Scholar
• Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am. J. Cardiol.98, 71i–76i (2006).
   PubMed Web of Science ®Google Scholar
• Wendland E, Farmer A, Glasziou P, Neil A. Effect of alpha linolenic acid on cardiovascular risk markers: a systematic review. Heart92, 166–169 (2006).
   PubMed Web of Science ®Google Scholar
• Wilkinson P, Leach C, Ah-Sing EE et al. Influence of alpha-linolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype. Atherosclerosis181, 115–124 (2005).
   PubMed Web of Science ®Google Scholar
• Bryhn M, Hansteen H, Schanche T, Aakre SE. The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters. Prostaglandins Leukot. Essent. Fatty Acids75, 19–24 (2006).
   PubMed Web of Science ®Google Scholar
• Bays HE. Safety considerations with omega-3 fatty acid therapy. Am. J. Cardiol.99, 35C–43C (2007).
   PubMed Web of Science ®Google Scholar
• Brunton S, Collins N. Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietarty-supplement omega-3-fatty acids. Curr. Med. Res. Opin.23, 1139–1145 (2007).
   PubMed Web of Science ®Google Scholar
• Collins N, Tighe AP, Brunton SA, Kris-Etherton PM. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J. Am. Coll. Nutr. (2008) (In Press).
   Google Scholar
• Reliant Pharmaceuticals. Lovaza™ (omega-3-acid ethyl esters) capsules (2007).
   Google Scholar
• Vanschoonbeek K, Feijge MA, Paquay M et al. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler. Thrombos.: J. Vasc. Biol.24, 1734–1740 (2004).
   PubMed Web of Science ®Google Scholar
• Mueller BA, Talbert RL. Biological mechanisms and cardiovascular effects of omega-3 fatty acids. Clin. Pharm.7, 795–807 (1988).
   PubMedGoogle Scholar
• Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am. J. Cardiol.99, 44C–46C (2007).
   PubMed Web of Science ®Google Scholar
• Bender NK, Kraynak MA, Chiquette E, Linn WD, Clark GM, Bussey HI. Effects of Marine Fish Oils on the Anticoagulation Status of Patients Receiving Chronic Warfarin Therapy. J. Thromb. Thrombolysis5, 257–261 (1998).
   PubMed Web of Science ®Google Scholar
• Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronoary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis (2007) (In Press).
   Google Scholar
• Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr. Opin. Lipidol.17, 387–393 (2006).
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Shimano H, Memiya-Kudo M et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell Biol.21, 2991–3000 (2001).
   PubMed Web of Science ®Google Scholar
• Horton JD, Bashmakov Y, Shimomura I, Shimano H. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc. Natl Acad. Sci. USA95, 5987–5992 (1998).
   PubMed Web of Science ®Google Scholar
• Le Jossic-Corcos C, Gonthier C, Zaghini I, Logette E, Shechter I, Bournot P. Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids. Biochem. J.385, 787–794 (2005).
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Shimano H, Yahagi N et al. Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J. Biol. Chem.277, 1705–1711 (2002).
   PubMed Web of Science ®Google Scholar
• Kramer JA, LeDeaux J, Butteiger D et al. Transcription profiling in rat liver in response to dietary docosahexaenoic acid implicates stearoyl-coenzyme a desaturase as a nutritional target for lipid lowering. J. Nutr.133, 57–66 (2003).
   PubMed Web of Science ®Google Scholar
• Zaima N, Sugawara T, Goto D, Hirata T. Trans geometric isomers of EPA decrease LXRalpha-induced cellular triacylglycerol via suppression of SREBP-1c and PGC-1β. J. Lipid Res.47, 2712–2717 (2006).
   PubMed Web of Science ®Google Scholar
• Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am. J. Cardiol.98, 27i–33i (2006).
   PubMed Web of Science ®Google Scholar
• Dagnelie PC, Rietveld T, Swart GR, Stijnen T, van den Berg JW. Effect of dietary fish oil on blood levels of free fatty acids, ketone bodies and triacylglycerol in humans. Lipids29, 41–45 (1994).
   PubMed Web of Science ®Google Scholar
• Parks JS, Johnson FL, Wilson MD, Rudel LL. Effect of fish oil diet on hepatic lipid metabolism in nonhuman primates: lowering of secretion of hepatic triglyceride but not apoB. J. Lipid Res.31, 455–466 (1990).
   PubMed Web of Science ®Google Scholar
• Khan S, Minihane AM, Talmud PJ et al. Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J. Lipid Res.43, 979–985 (2002).
   PubMed Web of Science ®Google Scholar
• Chambrier C, Bastard JP, Rieusset J et al. Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obes. Res.10, 518–525 (2002).
   PubMedGoogle Scholar
• Leibowitz MD, Fievet C, Hennuyer N et al. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett.473, 333–336 (2000).
   PubMed Web of Science ®Google Scholar
• Zhao A, Yu J, Lew JL, Huang L, Wright SD, Cui J. Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. DNA Cell Biol.23, 519–526 (2004).
   PubMed Web of Science ®Google Scholar
• Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol.12, 297–304 (2001).
   PubMed Web of Science ®Google Scholar
• Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler. Thromb. Vasc. Biol.19, 472–484 (1999).
   PubMed Web of Science ®Google Scholar
• Claudel T, Inoue Y, Barbier O et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology125, 544–555 (2003).
   PubMed Web of Science ®Google Scholar
• Kast HR, Nguyen CM, Sinal CJ et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol.15, 1720–1728 (2001).
   PubMed Web of Science ®Google Scholar
• Sirvent A, Claudel T, Martin G et al. The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett.566, 173–177 (2004).
   PubMed Web of Science ®Google Scholar
• Durrington PN, Bhatnagar D, Mackness MI et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart85, 544–548 (2001).
   PubMed Web of Science ®Google Scholar
• Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes51, 2377–2386 (2002).
   PubMed Web of Science ®Google Scholar
• Nordoy A, Bonaa KH, Nilsen H, Berge RK, Hansen JB, Ingebretsen OC. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J. Intern. Med.243, 163–170 (1998).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Stein EA, Bays HE et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin. Ther.29, 1354–1367 (2007).
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Le NA, Gibson JC. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss. J. Clin. Invest.75, 614–623 (1985).
   PubMed Web of Science ®Google Scholar
• Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr.21, 495–505 (2002).
   PubMed Web of Science ®Google Scholar
• Zamaria N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod. Nutrit. Develop.44, 273–282 (2004).
   PubMedGoogle Scholar
• Cardoso CR, Souza MA, Ferro EA, Favoreto S Jr, Pena JD. Influence of topical administration of n-3 and n-6 essential and n-9 nonessential fatty acids on the healing of cutaneous wounds. Wound Rep. Reg.12, 235–243 (2004).
   PubMed Web of Science ®Google Scholar
• Logan AC. Omega-3 fatty acids and acne. Arch. Dermatol.139, 941–942 (2003).
   PubMed Web of Science ®Google Scholar
• DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud’s phenomenon: a double-blind, controlled, prospective study. Am. J. Med.86, 158–164 (1989).
   PubMed Web of Science ®Google Scholar
• Donadio JV Jr. Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease. Mayo Clin. Proc.66, 1018–1028 (1991).
   PubMed Web of Science ®Google Scholar
• Devereux G, Seaton A. Diet as a risk factor for atopy and asthma. J. Allergy Clin. Immunol.115, 1109–1117 (2005).
   PubMed Web of Science ®Google Scholar
• Donadio JV, Grande JP. The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin. Nephrol.24, 225–243 (2004).
   PubMed Web of Science ®Google Scholar
• Mickleborough TD. Dietary omega-3 polyunsaturated fatty acid supplementation and airway hyperresponsiveness in asthma. J. Asthma42, 305–314 (2005).
   PubMed Web of Science ®Google Scholar
• Mickleborough TD, Rundell KW. Dietary polyunsaturated fatty acids in asthma- and exercise-induced bronchoconstriction. Eur. J. Clin. Nutr.59, 1335–1346 (2005).
   PubMed Web of Science ®Google Scholar
• Wong KW. Clinical efficacy of n-3 fatty acid supplementation in patients with asthma. J. Am. Diet Assoc.105, 98–105 (2005).
   PubMed Web of Science ®Google Scholar
• Simopoulos AP. Essential fatty acids in health and chronic diseases. Forum of Nutrition56, 67–70 (2003).
   PubMedGoogle Scholar
• Curtis CL, Rees SG, Cramp J et al. Effects of n-3 fatty acids on cartilage metabolism. Proc. Nutrit. Soc.61, 381–389 (2002).
   PubMed Web of Science ®Google Scholar
• Saldeen P, Saldeen T. Women and omega-3 Fatty acids. Obstet. Gynecol. Surv.59, 722–730 (2004).
   PubMed Web of Science ®Google Scholar
• Bourre JM. Dietary omega-3 Fatty acids and psychiatry: mood, behaviour, stress, depression, dementia and aging. J. Nutr. Health Aging9, 31–38 (2005).
   PubMed Web of Science ®Google Scholar
• Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry68, 1056–1061 (2007).
   PubMed Web of Science ®Google Scholar
• Wozniak J, Biederman J, Mick E et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur. Neuropsychopharmacol.17, 440–447 (2007).
   PubMed Web of Science ®Google Scholar
• Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol. Psychiatr.61, 551–553 (2007).
   PubMed Web of Science ®Google Scholar
• Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs65, 1051–1059 (2005).
   PubMed Web of Science ®Google Scholar
• Young G, Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod. Nutr. Develop.45, 1–28 (2005).
   PubMedGoogle Scholar
• Puri BK, Bydder GM, Counsell SJ et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport13, 123–126 (2002).
   PubMed Web of Science ®Google Scholar
• Schwarz S, Leweling H. Multiple sclerosis and nutrition. Multiple Sclerosis11, 24–32 (2005).
   PubMed Web of Science ®Google Scholar
• Ayton AK, Azaz A, Horrobin DF. A pilot open case series of ethyl-EPA supplementation in the treatment of anorexia nervosa. Prostaglandins Leukot. Essent. Fatty Acids71, 205–209 (2004).
   PubMed Web of Science ®Google Scholar
• Kitajka K, Sinclair AJ, Weisinger RS et al. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc. Natl Acad. Sci. USA101, 10931–10936 (2004).
   PubMed Web of Science ®Google Scholar
• Decsi T, Koletzko B. N-3 fatty acids and pregnancy outcomes. Curr. Opin. Clin. Nutr. Metab. Care8, 161–166 (2005).
   PubMed Web of Science ®Google Scholar
• Alessandri JM, Guesnet P, Vancassel S et al. Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod. Nutrit. Develop.44, 509–538 (2004).
   PubMedGoogle Scholar
• Bourre JM. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J. Nutr. Health Aging8, 163–174 (2004).
   PubMedGoogle Scholar
• SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog. Ret. Eye Res.24, 87–138 (2005).
   PubMed Web of Science ®Google Scholar
• Cho E, Hung S, Willett WC et al. Prospective study of dietary fat and the risk of age-related macular degeneration. Am. J. Clin. Nutr.73, 209–218 (2001).
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Fazzio M, Venturini P. Polyunsaturated fatty acids and risk of preterm delivery. Eur. Rev. Med. Pharmacol. Sci.9, 41–48 (2005).
   PubMedGoogle Scholar
• Gazvani MR, Smith L, Haggarty P, Fowler PA, Templeton A. High omega-3: omega-6 fatty acid ratios in culture medium reduce endometrial-cell survival in combined endometrial gland and stromal cell cultures from women with and without endometriosis. Fertil. Steril.76, 717–722 (2001).
   PubMed Web of Science ®Google Scholar
• Terry PD, Rohan TE, Wolk A. Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. Am. J. Clin. Nutr.77, 532–543 (2003).
   PubMed Web of Science ®Google Scholar
• Terry PD, Terry JB, Rohan TE. Long-chain (n-3) fatty acid intake and risk of cancers of the breast and the prostate: recent epidemiological studies, biological mechanisms, and directions for future research. J. Nutr.134, 3412S–3420S (2004).
   PubMed Web of Science ®Google Scholar
• Albino AP, Juan G, Traganos F et al. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation. Cancer Res.60, 4139–4145 (2000).
   PubMed Web of Science ®Google Scholar
• Cawood AL, Carroll MP, Wootton SA, Calder PC. Is there a case for n-3 fatty acid supplementation in cystic fibrosis? Curr. Opin. Clin. Nutr. Metab. Care8, 153–159 (2005).
   PubMed Web of Science ®Google Scholar
• Tamizi fB, Tamizi B. Treatment of chronic fatigue syndrome by dietary supplementation with omega-3 fatty acids – a good idea? Med. Hypotheses58, 249–250 (2002).
   PubMed Web of Science ®Google Scholar
• Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in Type 2 diabetes: a review. J. Am. Diet Assoc.105, 428–440 (2005).
   PubMed Web of Science ®Google Scholar
• Harris WS. Are omega-3 fatty acids the most important nutritional modulators of coronary heart disease risk? Curr. Atheroscler. Rep.6, 447–452 (2004).
   PubMedGoogle Scholar
• Mozaffarian D, Psaty BM, Rimm EB et al. Fish intake and risk of incident atrial fibrillation. Circulation110, 368–373 (2004).
   PubMed Web of Science ®Google Scholar
• Ismail HM. The role of omega-3 fatty acids in cardiac protection: an overview. Front. Biosci.10, 1079–1088 (2005).
   PubMed Web of Science ®Google Scholar
• Christensen JH. n-3 fatty acids and the risk of sudden cardiac death. Emphasis on heart rate variability. Dan. Med. Bull.50, 347–367 (2003).
   PubMedGoogle Scholar
• Schrepf R, Limmert T, Claus WP, Theisen K, Sellmayer A. Immediate effects of n-3 fatty acid infusion on the induction of sustained ventricular tachycardia. Lancet363, 1441–1442 (2004).
   PubMed Web of Science ®Google Scholar
• Geelen A, Zock PL, Brouwer IA et al. Effect of n-3 fatty acids from fish on electrocardiographic characteristics in patients with frequent premature ventricular complexes. Br. J. Nutr.93, 787–790 (2005).
   PubMed Web of Science ®Google Scholar
• Raitt MH, Connor WE, Morris C et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA293, 2884–2891 (2005).
   PubMed Web of Science ®Google Scholar
• Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am. J. Clin. Nutr.81, 50–54 (2005).
   PubMed Web of Science ®Google Scholar
• Lee KW, Hamaad A, MacFadyen RJ, Lip GY. Effects of dietary fat intake in sudden death: reduction of death with omega-3 fatty acids. Curr. Cardiol. Rep.6, 371–378 (2004).
   PubMedGoogle Scholar
• GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet354, 447–455 (1999).
   Google Scholar
• Burr ML, Fehily AM, Gilbert JF et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet2, 757–761 (1989).
   PubMed Web of Science ®Google Scholar
• He K, Song Y, Daviglus ML et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation109, 2705–2711 (2004).
   PubMed Web of Science ®Google Scholar
• Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am. J. Clin. Nutr.65, 1645S–1654S (1997).
   PubMed Web of Science ®Google Scholar
• Abbey M, Clifton P, Kestin M, Belling B, Nestel P. Effect of fish oil on lipoproteins, lecithin:cholesterol acyltransferase, and lipid transfer protein activity in humans. Arteriosclerosis10, 85–94 (1990).
   PubMedGoogle Scholar
• Lu G, Windsor SL, Harris WS. Omega-3 fatty acids alter lipoprotein subfraction distributions and the in vitro conversion of very low density lipoproteins to low density lipoproteins. J. Nutr. Biochem.10, 151–158 (1999).
   PubMed Web of Science ®Google Scholar
• Mori TA, Burke V, Puddey IB et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am. J. Clin. Nutr.71, 1085–1094 (2000).
   PubMed Web of Science ®Google Scholar
• Suzukawa M, Abbey M, Howe PR, Nestel PJ. Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J. Lipid Res.36, 473–484 (1995).
   PubMed Web of Science ®Google Scholar
• Rivellese AA, Maffettone A, Vessby B et al. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects. Atherosclerosis167, 149–158 (2003).
   PubMed Web of Science ®Google Scholar
• Calabresi L, Villa B, Canavesi M et al. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism53, 153–158 (2004).
   PubMed Web of Science ®Google Scholar
• Sanders TA. Dietary fat and postprandial lipids. Curr. Atheroscler. Rep.5, 445–451 (2003).
   PubMedGoogle Scholar
• von Schacky C. The role of omega-3 fatty acids in cardiovascular disease. Curr. Atheroscler. Rep.5, 139–145 (2003).
   PubMedGoogle Scholar
• Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J. Am. Soc. Nephrol.13, 184–190 (2002).
   PubMed Web of Science ®Google Scholar
• Cartwright IJ, Pockley AG, Galloway JH, Greaves M, Preston FE. The effects of dietary omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis55, 267–281 (1985).
   PubMed Web of Science ®Google Scholar
• Kaminski WE, Jendraschak E, Kiefl R, von Schacky C. Dietary omega-3 fatty acids lower levels of platelet-derived growth factor mRNA in human mononuclear cells. Blood81, 1871–1879 (1993).
   PubMed Web of Science ®Google Scholar
• Mayer K, Merfels M, Muhly-Reinholz M et al. Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. Am. J. Physiol. Heart Circ. Physiol.283, H811–H818 (2002).
   PubMed Web of Science ®Google Scholar
• von Schacky C, Baumann K, Angerer P. The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. Lipids36(Suppl.), S99–S102 (2001).
   PubMed Web of Science ®Google Scholar
• Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr. Atheroscler. Rep.6, 461–467 (2004).
   PubMedGoogle Scholar
• Kim DN, Eastman A, Baker JE et al. Fish oil, atherogenesis, and thrombogenesis. Ann. NY Acad. Sci.748, 474–480 (1995).
   PubMed Web of Science ®Google Scholar
• Sethi S. Inhibition of leukocyte-endothelial interactions by oxidized omega-3 fatty acids: a novel mechanism for the anti-inflammatory effects of omega-3 fatty acids in fish oil. Redox Rep.7, 369–378 (2002).
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. Lipoprotein metabolism and its relationship to atherosclerosis. Med. Clin. North Am.78, 1–20 (1994).
   PubMed Web of Science ®Google Scholar
• McKeone BJ, Osmundsen K, Brauchi D et al. Alterations in serum phosphatidylcholine fatty acyl species by eicosapentaenoic and docosahexaenoic ethyl esters in patients with severe hypertriglyceridemia. J. Lipid Res.38, 429–436 (1997).
   PubMed Web of Science ®Google Scholar
• Abe Y, El-Masri B, Kimball KT et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler. Thromb. J. Vasc. Biol.18, 723–731 (1998).
   PubMed Web of Science ®Google Scholar
• Pownall HJ, Brauchi D, Kilinc C et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis143, 285–297 (1999).
   PubMed Web of Science ®Google Scholar
• Westphal S, Orth M, Ambrosch A, Osmundsen K, Luley C. Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids. Am. J. Clin. Nutr.71, 914–920 (2000).
   PubMed Web of Science ®Google Scholar
• Stalenhoef AF, de GJ, Wittekoek ME, Bredie SJ, Demacker PN, Kastelein JJ. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis153, 129–138 (2000).
   PubMed Web of Science ®Google Scholar